TY  - JOUR
AU  - Lluch, A
AU  - Manso, L
AU  - Calvo, I
AU  - Cortes, J
AU  - Garcia-Saenz, J A
AU  - Gil-Gil, M
AU  - Martinez-Janez, N
AU  - Apala, J V
AU  - Ximénez-Embún, Pilar
AU  - Muñoz, J
AU  - Gonzalez-Cortijo, L
AU  - Murillo, R
AU  - Sánchez-Bayona, R
AU  - Cejalvo, J M
AU  - Fustero-Torre, C
AU  - Sabroso-Lasa, S
AU  - Martinez, M
AU  - Moreno, A
AU  - Colomer, R
AU  - Mouron, Silvana Andrea
AU  - Bueno Verdejo, Maria Jose
AU  - Caleiras, E
AU  - Gomez Lopez, Gonzalo
AU  - Malats, Nuria
AU  - Megias Vazquez, Diego
AU  - Malumbres Martinez, Marcos
AU  - Quintela Fandino, Miguel Angel
PY  - 2022
DO  - 10.1038/s41467-022-35065-z
UR  - http://hdl.handle.net/20.500.12105/16031
AB  - Precision oncology research is challenging outside the contexts of oncogenic addiction and/or targeted therapies. We previously showed that phosphoproteomics is a powerful approach to reveal patient subsets of interest characterized by the activity of...
LA  - eng
PB  - Nature Publishing Group
KW  - Paclitaxel
KW  - Breast Neoplasms
KW  - Humans
KW  - Female
KW  - Precision Medicine
KW  - Genomics
KW  - Cyclin-Dependent Kinase 4
TI  - Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A.
TY  - journal article
ER  -